Wall Street Zen Downgrades Pharvaris (NASDAQ:PHVS) to Strong Sell

Key Points

• Wall Street Zen downgraded Pharvaris (NASDAQ:PHVS) from a "sell" to a "strong sell" in a note to investors on Monday.
• Despite the downgrade, the street remains largely bullish—11 analysts rate PHVS a Buy (average consensus "Moderate Buy") with an average target of $42.73, implying roughly a 60% upside from Monday's open of $26.63.
• Insider activity: CEO Berndt Modig sold 23,333 shares at an average $27.74 for about $647k under a pre-arranged Rule 10b5-1 plan, reducing his reported stake by 14.1%.

Pharvaris (NASDAQ:PHVS - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "sell" rating to a "strong sell" rating in a note issued to investors on Monday.

A number of other research firms have also recently commented on PHVS. Weiss Ratings restated a "sell (d-)" rating on shares of Pharvaris in a research note on Thursday, January 22nd. HC Wainwright restated a "buy" rating and issued a $60.00 target price on shares of Pharvaris in a research note on Tuesday, March 3rd. Royal Bank Of Canada lowered their target price on Pharvaris from $52.00 to $51.00 and set an "outperform" rating for the company in a research note on Monday, April 6th. Wedbush raised their target price on Pharvaris from $41.00 to $42.00 and gave the company an "outperform" rating in a research note on Tuesday, April 7th. Finally, Wolfe Research assumed coverage on Pharvaris in a research note on Thursday. They issued an "outperform" rating and a $42.00 target price for the company. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Pharvaris currently has an average rating of "Moderate Buy" and an average target price of $42.73.

Pharvaris Price Performance

PHVS opened at $26.63 on Monday. The stock has a market cap of $1.74 billion, a PE ratio of -7.90 and a beta of -2.58. The business has a 50 day moving average of $27.05 and a 200-day moving average of $25.53. Pharvaris has a 52 week low of $11.66 and a 52 week high of $29.85.

Insiders Place Their Bets

In related news, CEO Berndt Modig sold 23,333 shares of Pharvaris stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $27.74, for a total transaction of $647,257.42. Following the transaction, the chief executive officer directly owned 142,084 shares in the company, valued at approximately $3,941,410.16. The trade was a 14.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Hedge Funds Weigh In On Pharvaris

Several institutional investors and hedge funds have recently bought and sold shares of the stock. General Atlantic L.P. lifted its position in Pharvaris by 6.6% during the third quarter. General Atlantic L.P. now owns 8,031,252 shares of the company's stock valued at $200,380,000 after purchasing an additional 500,000 shares in the last quarter. Foresite Capital Management IV LLC lifted its position in Pharvaris by 8.3% during the third quarter. Foresite Capital Management IV LLC now owns 4,778,581 shares of the company's stock valued at $119,226,000 after purchasing an additional 368,000 shares in the last quarter. venBio Partners LLC lifted its position in Pharvaris by 8.2% during the third quarter. venBio Partners LLC now owns 4,639,304 shares of the company's stock valued at $115,751,000 after purchasing an additional 350,000 shares in the last quarter. Deerfield Management Company L.P. lifted its position in Pharvaris by 21.1% during the third quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company's stock valued at $60,939,000 after purchasing an additional 425,000 shares in the last quarter. Finally, Commodore Capital LP lifted its position in Pharvaris by 26.5% during the third quarter. Commodore Capital LP now owns 2,418,476 shares of the company's stock valued at $60,341,000 after purchasing an additional 507,043 shares in the last quarter.

Trending Headlines about Pharvaris

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Wolfe Research initiated coverage with an "Outperform" rating and a $42 price target (~58% upside vs. current levels), which can boost investor interest and buying pressure. Wolfe Research initiates coverage of Pharvaris NV (PHVS) with outperform recommendation
• Positive Sentiment: Wedbush raised its price target on PHVS to $42, aligning with other bullish voices and reinforcing the street’s constructive view on Pharvaris' growth/valuation runway. Wedbush Increases Pharvaris NASDAQ: PHVS Price Target to $42.00
• Neutral Sentiment: HC Wainwright published earnings/long‑term model commentary for Pharvaris (estimating FY2030 figures and Q1 outlook). Analyst model updates can influence expectations but are not an immediate catalyst absent new clinical or commercial data. HC Wainwright Predicts Pharvaris FY2030 Earnings
• Neutral Sentiment: Reported short-interest data is effectively zero (no measurable short volume), so short-covering or squeeze dynamics are unlikely to be a driver in the near term. (Internal reporting entry.)
• Negative Sentiment: CEO Berndt Modig sold 23,333 shares (~14.1% reduction in his reported position) under a pre-arranged Rule 10b5-1 plan for proceeds ~ $647k. Insider sales can be interpreted negatively by some investors even when executed under 10b5-1 plans. SEC filing for insider sale

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.